Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylaminemephedrone, MDMA, amphetamine +1 moremephedrone, MDMA, amphetamine, methamphetamine show less
Clephedrone
4-CMC (4-chloromethcathinone) — also known as clephedrone — is a synthetic stimulant of the substituted cathinone class. It is the nearest chemical relative of mephedrone, with near-identical transporter potency but slower metabolic clearance.[1] It floods nerve terminals with dopamine, norepinephrine, and serotonin simultaneously, combining stimulant drive with empathogenic warmth.[2]
4-CMC (4-chloromethcathinone) — also known as clephedrone — is a synthetic stimulant of the substituted cathinone class. It is the para-chloro structural analog of mephedrone, with near-identical transporter potency but slower metabolic clearance.[1][2] 4-CMC is a non-selective monoamine releasing agent, producing its effects by driving simultaneous release of dopamine, norepinephrine, and serotonin from nerve terminals.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylaminemephedrone, MDMA, amphetamine +1 moremephedrone, MDMA, amphetamine, methamphetamine show less
4-CMC first appeared on the European drug market in June 2014 as a research chemical, introduced as a substitute after Mephedrone was banned.[3][4] Within years it became one of the most frequently seized synthetic cathinones in Europe, routinely sold mislabeled as MDMA, ketamine, or other cathinones.[5] It is now internationally controlled and was placed on Schedule I in the United States in December 2025.[6]
Subjective effects include stimulation, euphoria, mood elevation, sociability, and wakefulness.[7] The experience sits between a pure stimulant and an empathogen — social settings amplify warmth and openness, while solitary use foregrounds restless drive.[8] Post-use mood depression, strong urges to redose, and cardiovascular strain are characteristic unwanted effects.
4-CMC does not produce strong physical dependence, but the dopamine-releasing mechanism drives compulsive redosing — and repeated use produces escalating rather than diminishing effects.[8] The body clears it unusually slowly, so each redose builds on the last, compounding cardiovascular and psychological risk.[1] It is among the least studied synthetic cathinones in wide circulation; most safety knowledge comes from animal studies and forensic cases.[7]
History[edit]
Discovery
4-CMC was first described in the scientific literature in 2014, characterized from a commercially available online vendor sample.[3] It appeared on the European drug market in June 2014, part of a wave of para-halogenated cathinones introduced after mephedrone and flephedrone were scheduled across several European jurisdictions.[4]
Market emergence
4-CMC quickly filled the market gap left by mephedrone,[4] becoming one of the most frequently seized synthetic cathinones in Europe by the mid-2020s.[5][7] Spanish drug checking services documented it sold as 3-MMC, MDMA, ketamine, and other cathinones — a mislabeling pattern that significantly amplifies harm for users who dose expecting a different substance.[4]
Prohibition
China controlled 4-CMC in 2015. The United Kingdom's Psychoactive Substances Act covered it from 2016. International scheduling under the UN 1971 Convention followed in 2020.[9] The United States placed it on Schedule I effective December 17, 2025.[6]
The name clephedrone follows the naming convention for cathinones, combining chloro- and ephedrone. In unregulated markets, 4-CMC circulates by its alphanumeric code rather than any street name — typical of novel psychoactive substances that reached peak distribution before acquiring cultural identity. Its reputation is defined more by the substances it replaced and was sold as than by its own pharmacology.
Chemistry[edit]
Structural class
4-CMC belongs to the substituted cathinone family — synthetic β-keto amphetamines derived from cathinone, the psychoactive alkaloid in khat. It is the para-chloro structural analog of mephedrone, differing at a single position on the aromatic ring. This substitution preserves near-identical transporter potency while producing a distinct metabolic profile.[10][11] Its molecular formula is C₁₀H₁₂ClNO (197.66 g/mol).
The β-keto group shared by all cathinones slows how readily the compound crosses the blood-brain barrier compared to non-β-keto amphetamines.[12]
Stability
4-CMC is notably unstable in storage — it degrades at room temperature and even under refrigeration.[13] In a long-term stability study, 4-CMC was among the least stable substances tested.[14] Aged material may have reduced potency or contain breakdown products with unknown pharmacological effects.
Pharmacology[edit]
Mechanism of action
4-CMC works differently from cocaine. Instead of blocking neurotransmitter reuptake, it enters the dopamine, norepinephrine, and serotonin transporters and drives them in reverse — flooding the synapse with all three at once.[2] This triple release sits between purely dopaminergic stimulants and serotonin-dominant empathogens like MDMA.[10]
In vivo effects
In animal studies, 4-CMC produced dose-dependent blood pressure and heart rate elevation comparable to mephedrone at equivalent doses.[2] Its balanced monoamine release drove horizontal locomotor activity rather than the repetitive, stereotyped movement typical of dopamine-selective cathinones.[15]
Pharmacokinetics
The defining pharmacokinetic feature is slow clearance — 4-CMC is eliminated by the body more slowly than most other cathinones.[1] Drug levels build with repeated doses rather than declining between them. Formal human data are limited, but after oral administration, high levels of unchanged drug persist in urine for at least 5 hours.[16][17][7]
Neuroscience[edit]
Where it acts
4-CMC releases dopamine in the brain's reward circuit, norepinephrine in the arousal system, and serotonin across regions governing mood and social behavior.[2] Dopamine drives euphoria and motivation. Norepinephrine raises heart rate and blood pressure and generates wakefulness. Serotonin adds warmth and emotional openness but depletes reserves that sustain mood afterward.
Why it matters
The dopamine-serotonin balance distinguishes 4-CMC from purely stimulant drugs. Dopamine drives the craving and reward; serotonin modulates it with warmth. This balance may reduce extreme compulsive redosing relative to dopamine-only stimulants[8] — but does not eliminate it.
With repeated use, the stimulant effect grows stronger rather than weaker.[8] This sensitization is the opposite of tolerance, and in the dopamine system it signals a restructuring toward drug-seeking behavior.
Critical gaps remain. The body clears 4-CMC slowly,[1] but whether this produces unusually high brain accumulation is unknown. Whether repeated use causes lasting damage to monoamine-producing nerve cells — suggested by cell toxicity data[15] — remains entirely unstudied in living organisms.
Subjective Effects[edit]
4-CMC sits between stimulant drive and empathogenic warmth. The balance shifts with intensity — lower amounts produce clean energy and elevated mood; higher amounts bring prosocial openness and emotional connection. Social settings amplify the empathogenic quality; solitary use tends toward restless stimulation.
The nearest well-known comparison is mephedrone — the two share near-identical receptor potency.[2] 4-CMC's distinctively slow clearance[1] means the experience builds more gradually and lasts longer, and effects from repeated doses can compound in unpredictable ways.
First characterized in 2014 from an online research chemical sample,[3] 4-CMC emerged amid a wave of para-halogenated cathinones designed to replace newly scheduled predecessors. It rapidly became one of the most frequently seized synthetic cathinones in Europe, often sold mislabeled as MDMA, ketamine, or other cathinones.[4][5] It is now internationally controlled under the UN 1971 Convention and was placed on Schedule I in the United States in December 2025.[6]
Subjective effects include stimulation, euphoria, mood elevation, sociability enhancement, and wakefulness.[5] The experience occupies a middle ground between pure stimulant drive and empathogenic warmth — shaped by balanced dopamine and serotonin release, and modulated by social context.[7] Post-use mood depression, compulsive redosing urges, and cardiovascular strain are characteristic unsought effects.
No physical dependence data exist in humans, though animal studies show behavioral sensitization rather than tolerance — a pattern associated with escalating use.[7] The compound's unusually low metabolic clearance means repeated doses accumulate in the body, compounding cardiovascular and psychological risk with each redose.[2] 4-CMC is among the most poorly characterized widely circulated synthetic cathinones — no clinical trials exist, and the first controlled human observation involved only eight participants.[5]
History[edit]
Discovery
4-CMC was first described in the scientific literature in 2014 by Taschwer et al., who characterized a commercially available sample purchased from an online vendor.[3] The compound had appeared on the European drug market in June 2014 as a research chemical, part of a wave of para-halogenated cathinones that emerged after the scheduling of mephedrone and flephedrone in several European jurisdictions.[8]
Market emergence
4-CMC functioned as a direct substitute for mephedrone in markets where the latter had been controlled.[8] By the mid-2020s it had become one of the most frequently seized synthetic cathinones in Europe.[4][5] Spanish drug checking services identified 4-CMC in 29 samples between 2014 and 2016, often sold misrepresented as 3-MMC, MDMA, ketamine, or other cathinones — a mislabeling pattern that significantly amplifies harm when users dose expecting a pharmacologically distinct substance.[8]
Prohibition
China controlled 4-CMC in 2015. The United Kingdom's Psychoactive Substances Act provided blanket coverage from 2016. International scheduling under the UN 1971 Convention (Schedule II) followed in 2020.[9] The United States DEA published a final rule placing 4-CMC on Schedule I effective December 17, 2025, citing high abuse potential, no accepted medical use, and lack of accepted safety under medical supervision.[6]
The name clephedrone follows International Nonproprietary Name conventions for cathinones, combining chloro- and ephedrone (an older synonym for methcathinone). In unregulated markets, 4-CMC circulates under its alphanumeric code rather than any established street name — a pattern typical of novel psychoactive substances that reached peak distribution before acquiring cultural identity.
Chemistry[edit]
Structural class
4-CMC belongs to the substituted cathinone family — synthetic β-keto amphetamines derived from cathinone, the principal psychoactive alkaloid of Catha edulis (khat). The compound is the 4-chloro structural analog of methcathinone, differing from mephedrone only at the para-ring position: chlorine replaces the methyl group. This single substitution alters lipophilicity and electronic properties while producing near-identical transporter potency but distinct metabolic behavior.
Within the structure-activity framework for 4-substituted methcathinones, the chloro substituent — a large, moderately electronegative halogen — produces a balanced dopamine/serotonin selectivity profile intermediate between the fluorine analogue (flephedrone, more serotonin-preferring) and the methyl analogue (mephedrone, slightly more dopamine-preferring).[10][11]
Molecular identity
| Molecular formula | C₁₀H₁₂ClNO |
| Molecular weight | 197.66 g/mol |
The core structure comprises a phenylpropan-1-one backbone with a methylamino group at the α-carbon and a chlorine atom at the para-position of the aromatic ring. The β-keto group (carbonyl at the 1-position) distinguishes cathinones from amphetamines and reduces blood-brain barrier permeability relative to non-keto analogues.[12]
Stereochemistry
4-CMC contains one chirality center at the α-carbon, yielding R- and S-enantiomers. Commercially available material is a racemic mixture.[3] The pharmacologically active enantiomer has not been identified — no enantioselective pharmacological data exist, and validated analytical methods face persistent challenges including enantiomer instability in biological matrices.[13]
Stability
4-CMC is notably unstable in biological matrices: degradation occurs at room temperature and at refrigerated storage over extended periods.[14] In a 775-day stability study, 4-CMC was among the least stable substances tested at +4°C.[15] This instability has implications for both forensic interpretation and harm reduction — stored material may have reduced potency or contain degradation products of unknown pharmacology.
Pharmacology[edit]
Mechanism of action
4-CMC is a non-selective monoamine releasing agent that acts as a substrate at all three major monoamine transporters — the DAT (DAT), the NET (NET), and the SERT (SERT). Rather than blocking reuptake like cocaine, it enters the transporter and forces neurotransmitter release in reverse, flooding the synapse with dopamine, norepinephrine, and serotonin simultaneously.[1]
The compound is modestly dopamine-preferring but retains substantial serotonergic activity — an intermediate profile between purely dopaminergic stimulants and serotonin-dominant empathogens like MDMA.[10] Unlike non-β-keto amphetamines, 4-CMC does not appear to activate TAAR1, a class distinction that may influence its behavioral profile.[12]
The cardiovascular effects are mediated through α₁-adrenergic signaling (blood pressure elevation) and D₁ dopaminergic signaling (locomotor stimulation, heart rate elevation), as confirmed by antagonist studies in rats.[1]
In vivo effects
In telemetry-implanted rats, 4-CMC produced dose-dependent increases in blood pressure, heart rate, and locomotor activity comparable to mephedrone at equivalent doses.[1] A notable finding was transient hypothermia (body temperature decrease of approximately 1°C at the highest dose tested) — a response that contrasts with the hyperthermia seen with some other cathinones.
Locomotor studies in mice confirmed a profile consistent with balanced monoamine release: enhanced horizontal but not vertical movement, distinguishing 4-CMC from dopamine-selective cathinones that tend to produce stereotyped vertical activity.[16]
Pharmacokinetics
Formal pharmacokinetic parameters — half-life, peak concentration, bioavailability — have not been published for any route of administration. Limited human data derive from small observational studies using 100–150 mg oral doses.[5][17][18]
After oral administration, 4-CMC reaches peak concentration substantially later than intranasally administered cathinones — within 3 hours versus within the first hour for comparable compounds.[18] High levels of unchanged parent compound persist in urine at least 5 hours post-dose.[17]
The defining pharmacokinetic feature is 4-CMC's classification as a low-clearance compound — the body eliminates it slowly compared to most other cathinones.[2] This means 4-CMC accumulates with repeated dosing and has an extended detection window, making redosing substantially more dangerous than with faster-metabolized cathinones. The specific liver enzymes involved in its metabolism have not been identified.safety citation needed
Neuroscience[edit]
Where it acts
4-CMC drives dopamine release in the mesolimbic mesolimbic pathway (ventral tegmental area → nucleus accumbens), producing the compound's reinforcing and euphoric properties.[1] Simultaneous norepinephrine release through the locus coeruleus system generates wakefulness, alertness, and the peripheral sympathetic activation — elevated heart rate, blood pressure, dilated pupils — confirmed in animal studies.[1]
Serotonin release modulates affective tone, predicted to add empathogenic and prosocial warmth while also driving thermoregulatory disruption and post-use emotional deflation.
Why it matters
The balanced dopamine-serotonin release profile places 4-CMC at a pharmacological intersection: mesolimbic wanting (dopamine-driven motivation and reward) is modulated by serotonergic liking (emotional warmth and contentment). This balance may produce strong subjective reward while potentially limiting the extreme compulsive redosing seen with purely dopaminergic agents.[7]
Animal studies showing behavioral sensitization — increasing rather than decreasing locomotor response over 7 days of intermittent dosing — suggest the dopaminergic system adapts to 4-CMC in ways that could drive escalating use patterns.[7]
Critical gaps remain in the neuroscience of 4-CMC. The R- and S-enantiomers likely differ in their dopamine versus serotonin selectivity — as seen with other cathinones — but no enantioselective neural data exist. Whether the compound's low clearance[2] produces unusually high brain accumulation is unknown.
Subjective Effects[edit]
The 4-CMC experience occupies a middle ground between pure psychostimulation and empathogenic warmth. At lower doses, users report clean stimulant energy with mild mood enhancement; at higher doses the serotonergic component becomes more prominent, producing prosocial feelings and emotional openness that shift the experience toward the entactogenic end of the spectrum. Set and setting modulate this balance — social environments tend to draw out the empathogenic qualities, while solitary or task-focused contexts foreground the stimulant drive.
Pharmacologically, 4-CMC is the nearest relative to mephedrone among widely circulated synthetic cathinones — near-identical receptor potency but noticeably slower metabolism.[1][2] This slower clearance introduces a distinctive variable: effects may build and compound unpredictably with repeated dosing, and a second dose may feel qualitatively different from the first.
Effect Grid
Clear stimulant effects with noticeable energy, sociability enhancement, mood elevation, and euphoria. Cognitive euphoria and thought acceleration are prominent. Some users may experience empathy enhancement and emotional warmth consistent with the compound's balanced DAT/SERT release profile, though empathogenic effects are pharmacologically predicted rather than confirmed in human studies.
Cardiovascular stimulation becomes apparent — elevated heart rate and blood pressure. Appetite suppression is likely. Bruxism, dry mouth, and restlessness may emerge. Wakefulness and insomnia should be expected if dosed in the evening.
This is the only dose range studied in a controlled human setting (100-150 mg oral, Poyatos 2025, n=8). The compound's low clearance means plasma levels persist longer than expected — wait at least 2 hours before considering any redose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dry mouth · Insomnia · Heart rate perception changes · Body high · Restlessness · Physical fatigue · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Bruxism · Nausea · Headache · Sexual arousal enhancement · Nasal congestion · Dizziness · Tingling / electric sensations · Trembling · Vomiting · Nystagmus (eye wobbles)
Restlessness · Physical fatigue · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Bruxism · Nausea · Headache · Sexual arousal enhancement · Nasal congestion · Dizziness · Tingling / electric sensations · Trembling · Vomiting · Nystagmus (eye wobbles)
Motivation suppression · Focus enhancement · Motivation enhancement · Information processing enhancement · Cognitive dysphoria · Analysis enhancement · Confusion · Thought disorganization · Thought loops · Cognitive impairment
Cognitive dysphoria · Analysis enhancement · Confusion · Thought disorganization · Thought loops · Cognitive impairment
Irritability · Dysphoria · Anhedonia · Emotional lability
Communication enhancement · Social connection · Ego inflation · Trust enhancement
Timeline
Gradual emergence of mild alertness and subtle stimulation. Onset is notably slower than mephedrone or methylone — oral fluid data show delayed peak relative to other cathinones.
Building stimulation with mood elevation and sociability increase. Cardiovascular effects (heart rate, blood pressure elevation) become noticeable. Energy and cognitive effects intensify.
Full stimulant and potential empathogenic effects. Maximum cardiovascular stimulation. Euphoria, energy, thought acceleration, and sociability at their highest.
Gradual reduction of stimulant effects. Residual cardiovascular elevation persists. Irritability, mild dysphoria, or emotional lability may emerge as serotonergic tone declines.
Post-stimulant period with possible fatigue, low mood, and irritability from serotonin depletion. Residual insomnia and restlessness may persist.
⚠ Avoid driving for at least 8 hours after last dose — residual stimulation and emerging fatigue may impair judgment and reaction time.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- 7 days
- Physical
- Negligible
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- mephedrone · MDMA · amphetamine
Toxicity
Acute toxicity
No lethal dose data exist for 4-CMC in any species. Computational modeling predicts significant acute toxicity, potential DNA damage, and heart rhythm disruption.[18][19] All toxicity thresholds are computational predictions only — no laboratory or clinical confirmation has been published.safety citation needed
Neurotoxicity
Laboratory studies on human nerve cells showed 4-CMC causes cell death through mitochondrial damage and energy depletion.[20] The concentrations required were far higher than those found in living users, making relevance at typical doses uncertain. Toxicity worsened with prolonged exposure rather than appearing immediately[15] — raising concern about cumulative damage from repeated use.
Cardiovascular effects
4-CMC raises blood pressure and heart rate in animals comparably to mephedrone.[2] Computational models predict heart rhythm disruption,[18] but no human heart monitoring data have been published.[7]
Blood cell effects
At concentrations found in serious cases, 4-CMC alters the surface properties of red blood cells and platelets.[21] Whether this affects clotting or circulation in living users is unknown.
Fatalities
Forensic blood concentrations from 15 cases showed overlap between survivors and fatalities — no blood concentration separates survivable from fatal exposure.[22]
A review of 27 CMC-related deaths in Kraków found all involved multiple substances.[23] No confirmed single-cause 4-CMC fatality has been published. The most detailed fatal case involved 4-CMC alongside a synthetic opioid and four other substances.[14]
Psychological risks
No controlled data on psychological adverse events exist for 4-CMC. Acute anxiety and agitation are expected at high doses, driven by norepinephrine and dopamine overstimulation. Post-use mood depression — low mood, irritability, poor concentration, disturbed sleep — follows from serotonin depletion, analogous to the MDMA comedown.
Compulsive redosing is driven by the dopamine-releasing mechanism.[2] Because 4-CMC clears slowly,[1] each additional dose accumulates in the body, escalating both cardiovascular and psychological risk.
inferred All psychological risk assessments are class-level inferences. No substance-specific human data exist.
Tolerance & Dependence
No human tolerance or dependence data exist for 4-CMC. In mice, repeated dosing produced sensitization rather than tolerance — the stimulant effect grew stronger over 7 days.[8] This reflects dopamine system changes associated with escalating drug-seeking. No significant withdrawal appeared in mice after 14 days, though psychological withdrawal in humans cannot be ruled out.[8]
4-CMC did not produce conditioned place preference in mice at tested doses.[8] This should not be read as evidence of low abuse potential — it is classified Schedule I based on real-world evidence.[6] Cross-tolerance with Mephedrone, MDMA, and amphetamine is pharmacologically expected but unconfirmed.inferred
Drug Interactions
No published human drug interaction studies exist for 4-CMC. All assessments are mechanism-based.
SSRIs and SNRIs may blunt 4-CMC's empathogenic effects while raising serotonin syndrome risk at high doses. Sertraline was present alongside 4-CMC in a fatal polydrug case.[14]
Other stimulants — Amphetamine, cocaine, other cathinones, MDMA — add cardiovascular strain when combined with 4-CMC. Polydrug stimulant use was a recurring finding in the Kraków fatality series.[23]
Opioids combined with 4-CMC carry extreme danger. The fatal case involving U-47700 alongside 4-CMC illustrates this risk.[14]
Lithium combined with serotonin-releasing agents raises seizure risk.citation needed
Blood pressure medications may be overcome by 4-CMC's blood pressure elevation,[2] producing unpredictable effects.
Enzyme inhibitors: 4-CMC already clears slowly;[1] anything that further slows its metabolism could significantly raise blood levels — a dangerous interaction that cannot currently be predicted.safety citation needed
Contraindications
7 knownNo substance-specific contraindication data exist. All are inferred from its pharmacological profile.
Absolute contraindications:
- Concurrent MAOI use — risk of fatal serotonin syndrome and blood pressure crisis[24]
- Serious heart conditions (uncontrolled high blood pressure, recent heart attack, heart failure, known rhythm disorders) — 4-CMC significantly elevates blood pressure and heart rate[2] with predicted rhythm disruption risk[18]
Relative contraindications:
- Concurrent SSRI/SNRI use — elevated serotonin syndrome risk
- Seizure disorders — monoamine releasers lower seizure threshold
- Liver impairment — 4-CMC already clears slowly; impaired liver function could produce dangerous accumulation[1]
- Pregnancy and breastfeeding — no safety data; monoamine releasers are presumed harmful to fetal developmentsafety citation needed
- Bipolar or psychotic disorders — dopamine and norepinephrine stimulation may trigger manic or psychotic episodes
inferred All contraindications are class-level inferences. No substance-specific studies have been published.
Harm Reduction[edit]
Forms & Identification
4-CMC's most consequential harm reduction challenge is frequent mislabeling. Drug checking services documented it sold as 3-MMC, MDMA, ketamine, and other cathinones.[4] Reagent testing can narrow the field but cannot definitively distinguish between closely related isomers without laboratory analysis.
Material that has changed color, consistency, or smell should be treated with extra caution. 4-CMC degrades at room temperature and even under refrigeration.[13] Degradation products are pharmacologically uncharacterized.
Guidelines
- Test before use. Reagent testing cannot confirm 4-CMC specifically but can rule out dangerous substitutions. Laboratory drug checking provides definitive identification where available.
- Start low, redose with extreme caution. 4-CMC is a low-clearance compound — each redose adds to existing drug levels rather than replacing a fading dose. Allow at least 3 hours after oral ingestion before assessing the full effect.
- Weigh doses precisely. Use a milligram-precision scale. Estimating crystalline powder by eye is unreliable.
- Hydrate moderately. Stimulant-empathogenic compounds promote both dehydration and, rarely, over-hydration from excessive drinking.
- Plan for a long experience. Slow clearance means effects persist longer than with most cathinones. Sleep may be difficult for hours after the primary effects fade.
- Avoid combining with other substances. Polydrug use was present in every published 4-CMC fatality.[23]
Set & Setting
4-CMC's dual stimulant-empathogenic character responds strongly to environment. Social settings amplify warmth and prosocial effects; solitary use tends toward restless stimulation that can tip into anxiety. The slow clearance[1] means the experience lasts longer than expected — planning for this reduces the risk of distressed redosing.
Aftercare & integration. The serotonin-releasing mechanism predicts a post-use period of reduced mood and emotional resilience — similar to the MDMA comedown. This may last 1–3 days and can include irritability, low motivation, difficulty concentrating, and disturbed sleep.
Physical recovery: Prioritize sleep, nutrition, and hydration in the 48 hours after use. Magnesium-rich foods or supplements may help with residual muscle tension. Avoid caffeine or additional stimulants during recovery.
Emotional recovery: Low mood during this period is a neurochemical consequence of temporary serotonin depletion, not a reflection of baseline mental state. If depressive symptoms persist beyond 3–5 days, or use is escalating, speak with a healthcare provider.
Recovery & Support
4-CMC's sensitization profile[8] — where the stimulant effect grows stronger with repeated use — can make escalating patterns difficult to recognize from the inside. Warning signs include shortening intervals between use, increasing doses, and continued use despite negative consequences.
No 4-CMC-specific treatment protocols exist. General stimulant recovery resources apply:
- SAMHSA National Helpline (US): 1-800-662-4357 — free, confidential, 24/7
- FRANK (UK): 0300 123 6600
- Cognitive behavioral therapy (CBT) has the strongest evidence base for stimulant use disorders
- Support groups including SMART Recovery and Narcotics Anonymous offer peer-based recovery frameworks
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Elevated heart rate, mild anxiety, and stimulation are expected and uncomfortable but not emergencies. Seek immediate help if any of the following occur:
- Chest pain or tightness
- Seizure or uncontrolled muscle jerking
- Loss of consciousness or unresponsiveness
- Body temperature hot enough to feel through clothing
- Severe confusion, paranoia, or inability to recognize surroundings
- Irregular heartbeat that feels different from simple fast heart rate
What to do:
- 1. Call emergency services immediately — do not wait to see if symptoms improve
- 2. Place an unconscious person in the recovery position (on their side, airway clear)
- 3. If overheating: remove excess clothing, apply cool water, move to a cooler environment
- 4. Do not restrain an agitated person unless there is immediate danger of self-harm
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (4-CMC, clephedrone, or synthetic cathinone), the approximate amount and time of ingestion, the route used, any other substances involved, and the symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for cathinone toxicity.
Legal Status[edit]
4-CMC is controlled in most major jurisdictions, internationally scheduled under the UN 1971 Convention since 2020.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II (1971 Convention) | Added 2020[9] |
| United States | Schedule I (Controlled Substances Act) | Final rule published November 17, 2025; effective December 17, 2025[6] |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Covered under blanket ban effective May 26, 2016citation needed |
| Germany | Controlled substance | Specific scheduling date not confirmed in published sourcescitation needed |
| China | Controlled | Scheduled October 2015citation needed |
| Australia | Narcotic | Requires import/export permitscitation needed |
| Canada | Not confirmed | National scheduling status could not be verified from available sources |
| Poland | Controlled (via UN 2020 scheduling) | Lacked specific national scheduling despite high domestic seizure rates until covered by international action[22][23] |
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- 7 days
- Physical
- Negligible
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- mephedrone · MDMA · amphetamine
Toxicity
Acute toxicity
No lethal dose data exist for 4-CMC in any species. Computational modeling predicts significant acute toxicity, potential for DNA damage, and risk of heart rhythm disruption via hERG channel inhibition.[19][20] All toxicity thresholds are computational predictions only — no laboratory or clinical confirmation has been published.safety citation needed
Neurotoxicity
Laboratory studies on human nerve cells showed that 4-CMC causes cell death through mitochondrial damage, energy depletion, and oxidative stress — with the para-chloro group specifically increasing toxicity compared to the unsubstituted parent compound.[21] The toxic concentration in these studies (~1.4 mM) substantially exceeds levels found in living users (0.007–0.38 µM) and even in fatalities (0.28–9.5 µM),[22] making the relevance at typical doses uncertain.
Toxicity intensified with prolonged exposure time rather than appearing immediately[16] — raising concern that repeated or chronic use patterns may produce cumulative nerve cell damage through mechanisms unrelated to the acute drug effect.
Cardiovascular effects
In rats, 4-CMC produced blood pressure and heart rate elevation comparable to mephedrone at equivalent doses.[1] Computational models predict potential for heart rhythm disruption,[19] though this has not been tested experimentally. No human heart monitoring data have been published beyond a single observational study that did not report ECG findings.[5]
Blood cell effects
At concentrations consistent with forensic cases, 4-CMC alters the surface properties of red blood cells and platelets.[23] The clinical significance — whether this affects clotting or circulation — is unknown.
Fatalities
Forensic blood concentrations from 15 cases ranged from 1.3 to 75.3 ng/mL in non-fatal cases and 56.2 to 1870 ng/mL in fatalities.[22] The overlap between these ranges means no blood concentration threshold separates survivable from fatal exposure.
A review of 27 CMC-related deaths in Kraków, Poland (2016–2022) found all involved multiple substances.[24] No confirmed monocause 4-CMC fatality has been published. A detailed fatal case involved 4-CMC alongside the synthetic opioid U-47700 and four other substances — the opioid concentration alone was consistent with lethal toxicity.[15]
Psychological risks
No controlled data on psychological adverse events exist for 4-CMC. The following risks are inferred from its pharmacological profile as a triple monoamine releaser:
- Acute anxiety and agitation are expected at high doses or in stressful environments, driven by norepinephrine and dopamine overstimulation
- Post-use mood depression following serotonin release predicts emotional lability, low mood, and irritability in the hours to days after use — analogous to the MDMA comedown
- Compulsive redosing is driven by the dopamine-releasing mechanism.[1] The compound's low clearance[2] means each subsequent dose adds to existing levels in the body, escalating both cardiovascular and psychological risk
inferred All psychological risk assessments are class-level inferences. No substance-specific human data exist.
Tolerance & dependence
No human tolerance or dependence data exist for 4-CMC.
Sensitization rather than tolerance: Repeated intermittent dosing in mice produced behavioral sensitization — the stimulant effect increased rather than decreased over 7 days.[7] This pattern reflects changes in the dopamine system associated with escalating drug-seeking behavior.
Reward and reinforcement: 4-CMC did not produce conditioned place preference in mice at tested doses, suggesting potentially lower rewarding properties than more dopamine-selective cathinones in this specific laboratory paradigm.[7] This finding should not be interpreted as evidence of low abuse potential in humans — the compound is classified as Schedule I based on extensive real-world abuse evidence.[6]
Withdrawal: No significant withdrawal symptoms were detected in mice following 14 days of intermittent treatment.[7] These negative findings do not rule out psychological withdrawal (craving, low mood) in humans following heavy use, particularly given the serotonin-releasing mechanism.
The balanced dopamine-serotonin activity theoretically reduces abuse liability relative to purely dopamine-selective agents,[10] though 4-CMC's dopamine-releasing potency is sufficient to produce robust reinforcement. Cross-tolerance with other monoamine releasers (Mephedrone, MDMA, amphetamine) is pharmacologically expected but has not been directly demonstrated.inferred
Drug Interactions
No published human drug interaction studies exist for 4-CMC. All interaction assessments are mechanism-based or class-extrapolated.
SSRIs and SNRIs: Serotonin reuptake inhibitors may blunt 4-CMC's serotonin-mediated effects while simultaneously raising serotonin syndrome risk at high doses. Sertraline was present alongside 4-CMC in a fatal polydrug case.[15]
Other stimulants: Amphetamine, cocaine, other cathinones, and MDMA produce additive cardiovascular strain when combined with 4-CMC. Polydrug cathinone use was a recurring finding in the Kraków fatality series.[24]
Opioids: While not a direct pharmacological interaction, the fatal case involving U-47700 alongside 4-CMC demonstrates the extreme danger of stimulant-opioid combinations.[15]
Lithium: Serotonin-releasing agents combined with lithium increase seizure risk; the combination is generally contraindicated for this class.citation needed
Blood pressure medications: 4-CMC's blood pressure elevation[1] may overcome antihypertensive medications, producing unpredictable effects.
Enzyme inhibitors: The liver enzymes that metabolize 4-CMC are unknown. Given its already slow clearance,[2] drugs that further slow metabolism could significantly increase blood levels — a potentially dangerous interaction that cannot currently be predicted.safety citation needed
Contraindications
7 knownNo substance-specific contraindication data exist for 4-CMC. The following are inferred from its pharmacological profile as a monoamine releaser with cardiovascular stimulant properties.
Absolute contraindications:
- Concurrent MAOI use (including moclobemide, phenelzine, tranylcypromine, selegiline at antidepressant doses) — risk of fatal serotonin syndrome and blood pressure crisis[25]
- Serious heart conditions (uncontrolled high blood pressure, recent heart attack, heart failure, known rhythm disorders) — 4-CMC produces significant blood pressure and heart rate elevation[1] with predicted heart rhythm disruption risk[19]
Relative contraindications:
- Concurrent SSRI/SNRI use — elevated serotonin syndrome risk
- Seizure disorders — monoamine releasers lower seizure threshold
- Liver impairment — 4-CMC is already slowly cleared; impaired liver function could produce dangerous accumulation[2]
- Pregnancy and breastfeeding — no safety data exist; monoamine releasers are presumed harmful to fetal developmentsafety citation needed
- Bipolar disorder or psychotic disorders — dopamine and norepinephrine stimulation may trigger manic or psychotic episodes
inferred All contraindications are class-level inferences. No substance-specific studies have been published.
Harm Reduction[edit]
Forms & Identification
4-CMC's most consequential harm reduction challenge is its frequent mislabeling. Drug checking services have documented it sold as 3-MMC, MDMA, ketamine, and other cathinones[8] — substances with very different dose ranges and pharmacological profiles. Reagent testing can narrow the field but cannot definitively distinguish between positional isomers (3-CMC vs 4-CMC) without laboratory analysis.
The compound's instability during storage[14] means aged material may have degraded, producing unknown byproducts. Material that has changed color, consistency, or smell from when it was obtained should be treated with additional caution.
Guidelines
- Test before use. Reagent testing cannot confirm 4-CMC specifically but can rule out dangerous substitutions. Laboratory drug checking services provide definitive identification where available.
- Start low, redose with extreme caution. 4-CMC is a low-clearance compound — each redose adds to existing drug levels rather than replacing a fading dose. Allow at least 3 hours after oral ingestion before considering whether the full effect has been reached.
- Weigh doses precisely. Use a milligram-precision scale. Volumetric estimation of crystalline powder is unreliable.
- Hydrate moderately. Stimulant-empathogenic compounds can promote both dehydration (through physical activity and suppressed thirst cues) and, rarely, over-hydration if users drink excessively.
- Plan for a long experience. The slow clearance means effects persist longer than with most cathinones, and sleep may be difficult for hours after the primary effects have faded.
- Avoid combining with other substances. Polydrug use was present in every published 4-CMC fatality.[24]
Set & Setting
4-CMC's dual stimulant-empathogenic character responds strongly to context. Social settings tend to amplify prosocial and empathogenic effects, while solitary use tends to produce restless stimulation that can tip into anxiety. The compound's extended duration due to slow clearance[2] means planning for a longer experience than expected — including the inability to sleep for several hours after effects subside — reduces the risk of distressed redosing.
Aftercare & integration. The serotonin-releasing mechanism predicts a post-use period of reduced mood and emotional resilience — analogous to the MDMA comedown. This may last 1–3 days and can include irritability, low motivation, difficulty concentrating, and disturbed sleep.
Physical recovery: Prioritize sleep, nutrition, and hydration in the 48 hours following use. Magnesium-rich foods or supplements may help with residual muscle tension. Avoid caffeine or additional stimulants during recovery.
Emotional recovery: Low mood during this period is a neurochemical consequence of temporary serotonin depletion, not a reflection of baseline mental state. If depressive symptoms persist beyond 3–5 days, or if use patterns are escalating, consider speaking with a healthcare provider.
Recovery & Support
4-CMC's behavioral sensitization profile[7] — where the stimulant effect increases rather than decreases with repeated use — may contribute to escalating use patterns that are difficult to recognize from the inside. Warning signs include shortening intervals between use, increasing doses, and continued use despite negative consequences.
No 4-CMC-specific treatment protocols exist. General stimulant recovery resources apply:
- SAMHSA National Helpline (US): 1-800-662-4357 — free, confidential, 24/7
- FRANK (UK): 0300 123 6600
- Cognitive behavioral therapy (CBT) has the strongest evidence base for stimulant use disorders
- Support groups including SMART Recovery and Narcotics Anonymous offer peer-based recovery frameworks
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most people who take 4-CMC will experience elevated heart rate, mild anxiety, and stimulation — these are uncomfortable but expected. Seek immediate help if any of the following occur:
- Chest pain or tightness
- Seizure or uncontrolled muscle jerking
- Loss of consciousness or unresponsiveness
- Body temperature hot enough to feel through clothing
- Severe confusion, paranoia, or inability to recognize surroundings
- Irregular heartbeat that feels different from simple fast heart rate
What to do:
- 1. Call emergency services immediately — do not wait to see if symptoms improve
- 2. Place an unconscious person in the recovery position (on their side, airway clear)
- 3. If the person is overheating, cool actively: remove excess clothing, apply cool water, move to a cooler environment
- 4. Do not restrain a person who is agitated unless there is immediate danger of self-harm
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (4-CMC, clephedrone, or synthetic cathinone), the approximate amount and time of ingestion, the route of administration, any other substances involved, and the symptoms observed. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for cathinone toxicity.
Legal Status[edit]
4-CMC is internationally controlled under Schedule II of the United Nations Convention on Psychotropic Substances (1971), following its addition in 2020.[9] Most major jurisdictions have implemented national controls either through specific scheduling or blanket psychoactive substance legislation. The regulatory trajectory lagged several years behind market emergence — 4-CMC was first detected in European drug markets in June 2014 but was not internationally scheduled until 2020.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II (1971 Convention) | Added 2020[9] |
| United States | Schedule I (Controlled Substances Act) | Final rule published November 17, 2025; effective December 17, 2025[6] |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Covered under blanket ban effective May 26, 2016citation needed |
| Germany | Controlled substance | Specific scheduling date not confirmed in published sourcescitation needed |
| China | Controlled | Scheduled October 2015citation needed |
| Australia | Narcotic | Requires import/export permitscitation needed |
| Canada | Not confirmed | National scheduling status could not be verified from available sources |
| Poland | Controlled (via UN 2020 scheduling) | Lacked specific national scheduling despite high domestic seizure rates until covered by international action[22][24] |
Frequently asked questions
What is Clephedrone?
Clephedrone is a synthetic substituted cathinone and non-selective monoamine releasing agent with stimulant and predicted empathogenic properties. First characterized in 2014, it was internationally scheduled in 2020 and placed in US Schedule I in 2025.
How long does Clephedrone last?
Total duration by route of administration — Oral: 4 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Clephedrone?
Psychedex publishes a dosage table for Clephedrone on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Clephedrone?
The highest-severity documented interactions for Clephedrone: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Clephedrone addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Clephedrone: tolerance builds none; full reset takes 7 days; cross-tolerance develops with mephedrone, MDMA, amphetamine, methamphetamine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3] ^abTaschwer M, Weiß JA, Kunert O, Schmid MG (2014) Analysis and characterization of the novel psychoactive drug 4-chloromethcathinone (clephedrone). — Forensic Science International doi:10.1016/j.forsciint.2014.09.007
- [4] ^abcdeGrifell M, Ventura M, Carbón X, Quintana P, Galindo L, Palma Á, Fornis I, Gil C, Farre M, Torrens M (2017) Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone). — Human Psychopharmacology doi:10.1002/hup.2621
- [5] ^abBerardinelli D, Taoussi O, Daziani G, Tavoletta F, Ricci G, Tronconi LP, Adamowicz P, Busardò FP, Carlier J (2024) 3-CMC, 4-CMC, and 4-BMC Human Metabolic Profiling: New Major Pathways to Document Consumption of Methcathinone Analogues? — The AAPS journal doi:10.1208/s12248-024-00940-8
- [6]
references
- [1]
- [2]
- [3] ^abcTaschwer M, Weiß JA, Kunert O, Schmid MG (2014) Analysis and characterization of the novel psychoactive drug 4-chloromethcathinone (clephedrone). — Forensic Science International doi:10.1016/j.forsciint.2014.09.007
- [4] ^abBerardinelli D, Taoussi O, Daziani G, Tavoletta F, Ricci G, Tronconi LP, Adamowicz P, Busardò FP, Carlier J (2024) 3-CMC, 4-CMC, and 4-BMC Human Metabolic Profiling: New Major Pathways to Document Consumption of Methcathinone Analogues? — The AAPS journal doi:10.1208/s12248-024-00940-8
- [5] ^abcdefPoyatos L, Núñez-Montero M, Hladun O, Rosa G, Martín S, Videla S, Martínez-Couselo S, Ventura M, La Maida N, Trana AD, Busardò FP, Torrens M, Pichini S, Pérez-Maña C, Farré M, Papaseit E (2025) Oral Fluid Concentrations and Pharmacological Effects of Clephedrone and Methylone in Humans. — International Journal of Molecular Sciences doi:10.3390/ijms27010089
- [6]